Corline Biomedical
15.40 SEK
-3.45 %
Less than 1K followers
CLBIO
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
-3.45 %
-5.81 %
-6.10 %
-10.47 %
+5.84 %
+60.75 %
+60.75 %
+9.22 %
+55.69 %
Corline Biomedical is active in the pharmaceutical industry. The company works with the substance heparin and has developed a portfolio of drug candidates for use in connection with organ and cell transplantation. The company sells its proprietary product CHS™ to medical technology customers, and is developing Renaparin® for use in regenerative medicine and organ transplantation. The headquarters are located in Uppsala.
Read moreMarket cap
402.45M SEK
Turnover
87.03K SEK
Revenue
7.65M
EBIT %
-192.81 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
8.5
2026
Interim report Q1'26
14.5
2026
General meeting '26
26.8
2026
Interim report Q2'26
All
Press releases
ShowingAll content types
Redeye: Corline Biomedical Q3 (Review) - Sales growth incoming
Redeye: Corline Biomedical - Kardium receives FDA approval
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools